세계의 ATP 분석 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

ATP Assays Market Size, Share & Trends Analysis Report By Type (Luminometric ATP Assays, Enzymatic ATP Assays), By Application (Drug Discovery & Development, Clinical Diagnostics), By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,641,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,094,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,998,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세계의 ATP 분석 시장 규모와 동향

세계의 ATP 분석 시장 규모는 2024년 35억 6,000만 달러로 추정되며, 2025-2030년까지 CAGR 7.91%를 보일 것으로 예측됩니다.

이 배경에는 신속하고 민감한 검출 방법에 대한 수요, 제약 및 생명 공학 연구의 용도 확대, 규제 당국의 승인, 만성 질환 부담 증가 등이 있습니다.

이러한 촉진요인은 의료, 연구, 산업 부문에서 ATP 측정법의 중요한 역할을 강조하는 것이며, 맞춤형 의료, 창약, 환경 모니터링, 식품 안전 및 품질 검사, 질병 관리에 있어서의 진보를 촉진합니다. 2002년 WHO 보고서에 따르면 식품 오염은 세계 약 6억 명에 영향을 미치고 있으며, 설사와 같은 심각한 증상을 포함한 연간 200개 이상의 질병으로 이어지며, 42만 명이 사망하고 3300만 명의 건강 수명이 손실되었습니다.

암, 당뇨병, 심혈관 장애, 감염증 등의 만성 질환의 유병률 증가가 진단 검사나 질병 관리에 있어서의 ATP 측정법 수요를 밀어 올리고 있습니다. 2023년 7월 발표한 보고서에 따르면 1억 1,600만명이 B형 간염에, 1,000만명이 C형 간염을 앓고 있으며, 암, 간경변, 바이러스성 간염과 관련 사망으로 이어지고 있습니다. ATP 수준은 세포 기능 장애와 질병의 진행을 나타내므로, 이러한 측정은 질병의 진단, 예후, 치료 반응의 모니터링을 위한 귀중한 툴이 됩니다.

오염된 식품에는 박테리아, 바이러스, 기생충, 화학물질 등의 유해한 병원체가 포함되어 있으며, 심각한 건강 위험을 초래합니다. 이 분석은 아데노신 삼인산을 측정합니다. 청정도를 평가하기 위한 신뢰할 수 있는 마커로 기능합니다. 이 제품은 위생 습관을 모니터링하고, 세척 절차를 검증하고, 안전 기준 준수를 확인하며, 공급망 전체에서 식품의 품질과 안전성을 유지하기 위해 실시간 미생물 모니터링을 가능하게 합니다.

기술 혁신은 ATP 분석 산업을 전진시키는 데 있어 매우 중요한 역할을 하고 있습니다. 스트레스, 활성화, 세포 사멸을 받은 세포에서 방출되는 ATP를 검출하도록 설계된 생물 발광법입니다. 면역 반응 조절의 중요한 측면인 면역원성 세포 사멸을 유도할 수 있는 치료를 평가하기 위한 매우 중요한 바이오마커로서 기능합니다.

ATP 어세이 산업은 어세이의 감도, 편의성, 가격 향상을 목표로 하는 최근의 동향에 의해 현저한 제품 혁신과 확대를 목격하고 있습니다. HTS 바이어빌리티 분석 키트를 출시한 것을 들 수 있습니다. 이것은 제약 및 생명공학 연구에서 고성능 스크리닝(HTS) 용도의 지원에 주력하고 있는 것을 반영하고 있습니다. 이 분석은 CellTiter-Glo와 같은 프리미엄 시장의 대체품에 필적하는 성능을 제공하는 한편, 보다 이용하기 쉬운 가격대에 자리매김하고 있는 것입니다. ATP 분석 산업 전체의 성장 궤도를 지원할 것으로 기대됩니다. 또한, 사용자 친화적이고 비용 효율적인 분석에 대한 주목은 다양한 연구 및 품질 검사 영역에서 실시간으로 확장 가능하고 고효율의 세포 생존율과 대사 연구를 가능하게 하는 방향으로 시장 이동과 일치하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 ATP 분석 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 상위 시장 전망
  • 보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석
• COVID-19에 의한 ATP 분석 시장에 대한 영향
• 지역 수준의 가격 분석
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

제4장 ATP 분석 시장 : 유형별, 추정 및 동향 분석

• 부문 대시보드
• ATP 분석 시장 : 유형 변동 분석, 2024년 및 2030년
  • 발광 ATP 분석
  • 효소 ATP 분석
  • 세포 기반 ATP 분석
  • 기타
  • 글래스퍼 및 클립

제5장 ATP 분석 시장 : 용도별, 추정 및 동향 분석

• 부문 대시보드
• ATP 분석 시장 : 용도 변동 분석, 2024년 및 2030년
  • 의약품의 발견과 개발
  • 임상 진단
  • 환경 검사
  • 식품 안전성 및 품질 검사
  • 기타

제6장 ATP 분석 시장 : 최종 용도별, 추정 및 동향 분석

• 부문 대시보드
• ATP 분석 시장 : 최종 용도 변동 분석, 2024년 및 2030년
  • 제약 및 생명 공학 기업
  • 학술연구기관
  • 병원 및 진단 실험실

제7장 ATP 분석 시장 : 지역별, 추정 및 동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 기업의 시장 점유율 분석, 2024년
  • Thermo Fisher Scientific
  • Promega Corporation
  • PerkinElmer Inc.
  • Becton, Dickinson and Company(BD)
  • Lonza Group Ltd.
  • Danaher Corporation
  • Abcam plc
  • Quest Diagnostics Incorporated
  • Biomerieux SA
  • 3M Company

>JHS

영문 목차

영문목차

ATP Assays Market Size & Trends:

The global ATP assays market size was estimated at USD 3.56 billion in 2024 and is projected to grow at a CAGR of 7.91% from 2025 to 2030. This is attributed to the demand for rapid and sensitive detection methods, expanding applications in pharmaceutical and biotechnology research, regulatory approvals, and the rising burden of chronic diseases.

These drivers underscore the critical role of ATP assays in healthcare, research, and industrial sectors, facilitating advancements in personalized medicine, drug discovery, environmental monitoring, food safety and quality testing, and disease management. The 2022 WHO report highlights that food contamination affects about 600 million people globally, leading to over 200 diseases annually, including severe conditions such as diarrhea, resulting in 420,000 deaths and 33 million healthy life years lost.

The increasing prevalence of chronic diseases, such as cancer, diabetes, cardiovascular disorders, and infectious diseases, drives the demand for ATP assays in diagnostic testing and disease management. According to the report published by World Health Organization (WHO) in July 2023, 116 million people live with hepatitis B and 10 million with hepatitis C, leading to cancer, liver cirrhosis, and viral hepatitis-related deaths, and around 3 million new infections occur annually, with most going undetected in the Western Pacific Region. ATP levels are indicative of cellular dysfunction and disease progression, making these assays valuable tools for disease diagnosis, prognosis, and monitoring therapeutic responses. As healthcare systems worldwide face the challenge of managing chronic conditions, assays contribute to improving patient outcomes through early detection and personalized treatment strategies.

Contaminated food contains harmful pathogens such as bacteria, viruses, parasites, and chemical substances, posing significant health risks. ATP assays are pivotal in combating food contamination by swiftly and sensitively detecting microbial presence. These assays measure adenosine triphosphate, a universal indicator of microbial activity found in all living cells. ATP levels serve as reliable markers for assessing cleanliness in food surfaces, equipment, and processing areas. They enable prompt identification of contamination sources, empowering food manufacturers, processors, and regulators to take immediate corrective actions to prevent foodborne illnesses. In food processing, these products monitor hygiene practices, validate cleaning procedures, ensure compliance with safety standards, and enable real-time microbial monitoring to uphold food quality and safety across supply chains.

Technological innovations play a pivotal role in driving the ATP assays industry forward. Advances in assay sensitivity, accuracy, and automation have enhanced the performance and reliability of AP detection methods. Manufacturers are developing novel platforms that integrate cutting-edge technologies such as bioluminescence, fluorescence, and chemiluminescence to provide rapid and precise measurements. For instance, The RealTime-Glo Extracellular ATP Assay by Promega Corporation is a bioluminescent method designed to detect ATP released from cells undergoing stress, activation, or apoptosis. It serves as a pivotal biomarker for assessing treatments that may induce immunogenic cell death, a significant aspect of immune response modulation. These advancements cater to the growing demand for high-throughput screening and automated workflows in research laboratories and diagnostic settings.

The ATP assays industry is witnessing notable product innovation and expansion, with recent developments aimed at enhancing assay sensitivity, convenience, and affordability. A key example is Biotium's launch of the Steady-ATP HTS Viability Assay Kit in March 2025, which reflects the industry's focus on supporting high-throughput screening (HTS) applications in pharmaceutical and biotech research. The newly launched assay offers ultra-high sensitivity, detecting as few as 16 cells per well in a 384-well format, and delivers a stable luminescent signal with an extended half-life of over 5 hours. Its single-step, homogeneous workflow is designed to simplify assay protocols, making it highly compatible with automation and HTS systems. Importantly, the assay delivers performance comparable to premium market alternatives, such as CellTiter-Glo, while being positioned at a more accessible price point. This development is expected to drive broader adoption of luminescent ATP assays, particularly in budget-sensitive research laboratories and emerging biotech companies, supporting the overall growth trajectory of the ATP assays industry. Furthermore, the focus on user-friendly and cost-effective assays aligns with the market's shift toward enabling real-time, scalable, and high-efficiency cell viability and metabolic studies across various research and quality testing domains.

Global ATP Assays Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global ATP assays market report based on type, application, end use, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Luminometric ATP Assays
• Enzymatic ATP Assays
• Bioluminescence Resonance Energy Transfer (BRET) ATP Assays
• Cell-based ATP Assays
• Others
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Drug Discovery & Development
• Clinical Diagnostics
• Environmental Testing
• Food Safety & Quality Testing
• Others
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Hospital & Diagnostics Laboratories
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Norway
  • Sweden
  • Denmark
  • Spain
  • Italy
  • France
  • Germany
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Application Outlook
  • 2.2.3. End Use Outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. ATP Assays Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Industry Analysis - Porter's
    • 3.2.3.1. Bargaining power of the suppliers
    • 3.2.3.2. Bargaining power of the buyers
    • 3.2.3.3. Threats of substitution
    • 3.2.3.4. Threats from new entrants
    • 3.2.3.5. Competitive rivalry
  • 3.2.4. PESTEL Analysis
    • 3.2.4.1. Political landscape
    • 3.2.4.2. Economic and Social landscape
    • 3.2.4.3. Technological landscape
• 3.3. Impact of COVID 19 on ATP Assays market
• 3.4. Pricing Analysis, at Regional Level
  • 3.4.1. North America
  • 3.4.2. Europe
  • 3.4.3. Asia Pacific
  • 3.4.4. Latin America
  • 3.4.5. MEA

Chapter 4. ATP Assays Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. ATP Assays Market: Type Movement Analysis, 2024 & 2030 (USD Million)
  • 4.2.1. Luminometric ATP Assays
    • 4.2.1.1. Luminometric ATP Assays Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.2.2. Enzymatic ATP Assays
    • 4.2.2.1. Enzymatic ATP Assays Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.2.3. Cell-based ATP Assays
    • 4.2.3.1. Cell-based ATP Assays Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.2.4. Others
    • 4.2.4.1. Other Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 4.2.5. Graspers/ Clips

Chapter 5. ATP Assays Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. ATP Assays Market: Application Movement Analysis, 2024 & 2030 (USD Million)
  • 5.2.1. Drug Discovery and Development
    • 5.2.1.1. Drug Discovery and Development Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 5.2.2. Clinical Diagnostics
    • 5.2.2.1. Clinical Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.2.3. Environmental Testing
    • 5.2.3.1. Environmental Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.2.4. Food Safety and Quality Testing
    • 5.2.4.1. Food Safety and Quality Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.2.5. Others
    • 5.2.5.1. Other Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. ATP Assays Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. ATP Assays Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
  • 6.2.1. Pharmaceutical and Biotechnology Companies
    • 6.2.1.1. Pharmaceutical and Biotechnology Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.2. Academic and Research Institutes
    • 6.2.2.1. Academic and Research Institutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.3. Hospital and Diagnostics Laboratories
    • 6.2.3.1. Hospital and Diagnostics Laboratories Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. ATP Assays Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company market share analysis, 2024
  • 8.3.2. Thermo Fisher Scientific
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Type benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Promega Corporation
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Type benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. PerkinElmer Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Type benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Becton, Dickinson and Company (BD)
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Type benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Lonza Group Ltd.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Type benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Danaher Corporation
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Type benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Abcam plc
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Type benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Quest Diagnostics Incorporated
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Type benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Biomerieux SA
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Type benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. 3M Company
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Type benchmarking
    • 8.3.11.4. Strategic initiatives

관련자료